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1. Introduction 
 The first isolation of Helicobacter pylori (H. pylori) in 1980s by Marshall and Warren 
(Marshall & Warren, 1984) ushered in a new era in gastric microbiology, and, in conjunction 
with increased interest in the pathogenesis of gastroduodenal diseases, has led to important 
breakthroughs in medical care (Dunn et al., 1997).  
H. pylori is a spiral-shaped gram-negative flagellate bacterium that demonstrates bluntly 
rounded ends in gastric biopsy specimens (Goodwin et al., 1987). H. pylori organisms are 2.5 
to 5.0 µm long and 0.5 to 1.0 µm wide, with four to six polar sheathed flagellas, which are 
essential for bacterial motility (Goodwin & Armstrong, 1990).  
H. pylori was the first pathogenic microorganism that had its genome sequenced in two 
different strains. In 1997, H. pylori strain 26695 was firstly isolated from an English patient 
with chronic gastritis and then sequenced. It had a circular chromosome composed of 
1.667.867 base pairs (Tomb et al., 1997). In 1999, strain J99 was isolated from an American 
patient with duodenal ulcer and then sequenced. This presented a similar, overall genomic 
organization, gene order and prediction of proteomes when compared to strain 26695 (Alm 
et al., 1999). In 2006, a chronic atrophic gastritis strain, HPAG1, was isolated and sequenced 
from a Swedish old patient (Oh et al., 2006). More recently, strain G27 was isolated from an 
Italian patient and had a similar size to the other three strains (Baltrus et al., 2009). Finally, 
other strains were sequenced, such as Shi470, B128 and 98-10 (McClain et al., 2009; Thiberge 
et al., 2010).  
The finding of strain-specific genes from the comparison of the sequenced strains is in 
agreement with the earlier studies which demonstrated the high diversity of the H. pylori 
genome (Akopyanz et al., 1992; Han et al., 2003). Consequently, this high level of genetic 
diversity can be an important factor in its adaptation to the host stomach and also for the 
clinical outcome of the infection, an aspect that remains unclear. However, it is thought to 
involve an interplay between the virulence of the infecting strain, host genetics and 
environmental factors (Kabir, 2009) and experience with other bacterial pathogens suggests 
that H. pylori-specific factors may exist that influence the microorganism pathogenicity.  
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According to Yamaoka (2008), many putative virulence genes of H. pylori have been 
reported to determine clinical outcomes, and these are generally classified into three 
categories. The first one contains strain-specific genes, which are present in only some H. 
pylori strains. Among them, the best studied is the cag pathogenicity island (PAI), which 
encodes a bacterial type IV secretory apparatus (Censini et al., 1996). The second group is 
the phase-variable genes which the gene status can be changed during growth or in 
different conditions. Based on the comparison of the three first sequenced genomes of H. 
pylori, six genes encoding outer-membrane proteins (oipA, sabA, sabB, babB, babC and 
hopZ) are thought to undergo phase variation (Tomb et al., 1997; Alm et al., 1999; Oh et al., 
2006). The last group of genes is with variable structures and genotypes depending on the 
strain, as example the vacA gene. Besides, the structure of many genes differs between 
Western strains and East Asian strains, and the structural differences in some genes are 
reported to influence virulence (Lu et al., 2007; Yamaoka, 2008). So, in this chapter, among 
virulence factors are described and analysed urease, vacA, cagA, cagT and dupA genes.  
H. pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory 
cytokine production (Harris et al., 1996). It appears to function as both a colonization factor 
and a virulence factor (Dun et al., 1997). The urease C gene, or glmM gene (Foxall et al., 
1992), a particular region of the urease gene, is specific to H. pylori and can be used for 
primary identification of the microorganism (Moore et al., 1993). The urease gene can also be 
used to prove the heterogeneity of H. pylori strains. For instance, its heterogeneity can be 
seen by the diversity of patterns obtained by a restriction fragment length polymorphism 
(RFLP) of urease C and urease B genes, which is able to differentiate many strains presented 
in diverse pathologies, such as chronic gastritis and peptic ulcer, caused by this bacterium 
(Roesler et al., 2009).  
Other of the major determinants of H. pylori virulence is VacA (vacuolating cytotoxin), a 
toxin that induces cytoplasmic vacuolation in gastric cells (Figura et al., 1989), membrane 
channel formation, apoptosis and immunomodulation (Atherton et al., 1995; Cover & 
Blanke, 2005). The vacA gene is present in all strains and comprises of two variable parts. 
The s-region encodes the signal peptide and is located at the 5´end of the gene which exists 
as an s1 or s2 allele, while the m-region (middle) occurs as an m1 or m2 allele (van Door et 
al. 1998). The production of vacuolating cytotoxin is related to the mosaic combination of s 
and m allelic types and has been associated to specific genotypes with different outcomes 
(Telford et al., 1994; van Door et al., 1998).   
The cytotoxin-associated gene (cag) pathogenicity island (PAI) is approximately a 40-kb 
cluster of genes in the H. pylori chromosome and can be divided into two regions, cag I and 
cag II (Censini et al., 1996), according to a novel insertion sequence. This gene encodes a 
type IV secretion system, which delivers CagA into the cytosol of gastric epithelial cells 
through a rigid needle structure covered by CagY, a VirB10-homologous protein and CagT, 
a VirB7-homologous protein, at the base (Covacci & Rappuoli, 2000; Rohde et al., 2003). H. 
pylori cagA positive strains are associated with higher grades of inflammation and a 
significantly increased risk of developing gastric cancer (Parsonnet et al., 1997). cagT gene is 
found at the base of the outgrowing pilus of the type IV secretion system and is supposed to 
be responsible for binding to a cellular receptor to induce interleukine-8 secretion and eject 
CagA (Rohde et al., 2003).  
Finally, the duodenal ulcer promoting gene (dupA) was the first putative disease specific 
marker whose association was described using H. pylori strains obtained in both Asian 
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(Japan and Korea) and Western (Colombia) regions (Lu et al., 2005). dupA gene is suggested 
to be a vir homologue and encompasses the sequences jhp0917 and jhp0918, as described in 
strain J99. This gene is associated with interleukin-8 induction (Schmidt et al., 2009) and is  
possibly part of a yet unidentified type IV secretion system (Lu et al., 2005). The original 
description of dupA reported that its presence was inversely related to mucosal atrophy and 
gastric cancer (Zhang et al., 2008, Yamaoka, 2008).  
H. pylori is an universal distribution bacterium which affects more than half of the world 
population, and is considered an important public health problem. Even though its 
transmission pathways are not completely clarified (Rothenbacher et al., 1998), infection by 
H. pylori is usually acquired during childhood and is characterized as being chronic, with 
greater prevalence in developing countries in all ages (Kodaira et al., 2002).  
Colonization with H. pylori is not actually a disease but a condition that affects the relative 
risk of developing various clinical disorders of the upper gastrointestinal tract (Kusters et 
al., 2006) and, possibly, extradigestive disorders (Gasbarrini et al., 1999; Figura et al., 2010). 
In the first case, H. pylori infection is responsible for the development of chronic gastritis, 
peptic ulcers, mucosa associated lymphoid tissue (MALT lymphoma) and gastric 
adenocarcinoma (Ahmed & Sechi, 2005). Regarding to extradigestive diseases, H. pylori 
infection has been associated with iron-deficiency anemia (Capurso et al., 2001), idiopathic 
thrombocytopenic purpura (Pellicano et al., 2009; Arnold et al., 2009), cardiovascular 
diseases (Franceschi et al., 2009), hepatobiliary diseases (Isaeva et al., 2009; Pirouz et al., 
2009) and amongst others.  
Especially with regards to gastric cancer, the interest in H. pylori as a cause of this illness 
began after the pioneering discoveries of Marshall and Warren. Prior to the discovery of the 
organism, it was known that gastric adenocarcinomas typically arose in areas of gastritis. 
When the relationship between H. pylori and chronic gastritis was established, investigators 
began to take interest in the causal role of the bacterium in gastric cancer (Herrera & 
Parsonnet, 2009). Therefore, on the basis of numerous epidemiological studies, H. pylori 
infection has been shown to be associated with an increased risk of gastric adenocarcinoma 
development (Parsonnet et al., 1997; Sugiyama & Asaka, 2004). Evidence that the presence of 
H. pylori increases the risk of developing gastric cancer through atrophy and intestinal 
metaplasia has also been reported (Asaka et al., 1994; Kuipers, 1995), suggesting that H. 
pylori positive patients developed these conditions in a greater proportion than control 
subjects. Besides, research conducted in animal models (Zhou et al., 2004) demonstrated that 
the eradication of the bacteria could reduce the incidence of gastric cancer in mice that 
developed the disease by inoculation of strains of H. pylori and administration of low doses 
of carcinogenic agents. These findings suggest that eradication of these bacteria during 
precancerous lesions of the disease significantly can reduce the incidence of gastric cancer 
also in humans (Sugiyama & Asaka, 2004). Consequently, in 1994 the International Agency 
for Research on Cancer, World Health Organization, concluded that H. pylori has a causal 
link with gastric carcinogenesis and was defined as type I carcinogen, a definite cause of 
cancer in humans (IARC, 1994).  
Gastric cancer continues to be a major global health problem (Malfertheiner et al., 2010) and, 
despite the decreasing incidence and mortality rates observed worldwide over the last 50 
years, it still ranks as a leading cause of cancer-related deaths in many parts of the world 
(Nardone et al., 2004). As symptoms are often absent or nonspecific in patients with the 
early stages of the disease, gastric cancer is usually diagnosed in an advanced stage, when 
curative options are limited. With exceptions in countries that have developed screening 
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programs for early diagnoses, most patients reach treatment with cancers already in 
advanced stages (Hohenberger & Gretschel, 2003). Consequently, gastric cancer carries a 
poor prognosis, with an overall five-year survival rate of less than 20% (Bowles & Benjamin, 
2001). 
The vast majority of gastric cancers are adenocarcinomas, which can be prevalently divided 
into two types, the intestinal and the diffuse (Lauren, 1965), which corresponds, 
respectively, to the well-differentiated type and to the poorly-differentiated type, in the 
Japanese classification (Sugiyama & Asaka, 2004). In contrast to the diffuse type (Figure 1), 
often associated with familial distribution and developed in the stomach following chronic 
inflammation, especially in the cardia (Nardone et al., 2004), intestinal type 
adenocarcinomas (Figure 2) are generally thought to be preceded by a sequence of precursor 
lesions (Correa, 1975). The basic components of this process are chronic inflammation of the 
gastric mucosa, which slowly progresses through the premalignant stages of atrophic 
gastritis, intestinal metaplasia and dysplasia to gastric cancer (Figure 3) (Correa & 
Houghton, 2007). In respect to localization in the stomach, premalignant lesions are most 
frequently localized in the antrum in the transitional zone between the antrum and corpus 
(de Vries et al., 2007). 
Unlike patients with advanced gastric cancer, patients diagnosed in an early stage of the 
disease present an excellent prognostic, in which a five-year survival rate is more than 90%. 
This disorder is defined as the adenocarcinoma that is confined to the mucosa or 
submucosa, irrespective of lymph-node invasion (Everett & Axon, 1998). Many early gastric 
cancers are believed to go through a life cycle consisting of ulcerations, followed by healing, 
then reulceration, and some tumours remain at this early stage for years even without 
treatment (Everett & Axon, 1998). Nevertheless, some early tumours rapidly became 
advanced and it is one of the principal questions concerning gastric carcinogenesis  
(Figure 4). 
 
 
Fig. 1. Diffuse type adenocarcinoma 
 
Fig. 2. Intestinal type adenocarcinoma 
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Fig. 3. Sequence of precursor lesions of the intestinal type adenocarcinoma development 
 
 
Fig. 4. Early gastric cancer: healing, maintenance or progression. 
Have H. pylori virulence factors influenced this alteration? Why any tumour remains at an 
early stage for years even without treatment, or why they are able to heal by themselves, we 
do not know. Obviously, gastric carcinogenesis involves the interaction of the etiologic 
agent (H. pylori), the host characteristics and the external environment (Kabir, 2009), and, in 
this relationship, it should be considered the different strains of H. pylori and their virulence 
factors, important keys in the role of gastric carcinogenesis. Consequently, with the aim to 
try and understand better the mechanism of gastric carcinogenesis, especially concerning 
about the act of H. pylori , in which present studies have identified and analysed possible 
and essential differences among H. pylori strains derived from patients with early and 
advanced distal intestinal type gastric adenocarcinoma. Molecular biology techniques were 
? ? ?
Adenocarcinoma 
Helicobacter pylori 
Chronic gastritis 
Atrophic gastritis 
Intestinal metaplasia 
Displasia 
Host characteristics 
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used in order to amplify genes of this bacterium that act as virulence factors, comparing the 
results obtained in the two severities of illness. 
2. Clinical samples, methods and results 
2.1 Clinical samples 
Clinical isolates of H. pylori used in this study were obtained from the Laboratory of 
Pathology of the Centre of Diagnosis of Digestive Diseases, Faculty of Medical Sciences, 
State University of Campinas (UNICAMP), São Paulo, Brazil. Eighty nine paraffin wax-
embedded specimens of gastric tissue were analysed from a total of 89 patients: 31 of these 
were diagnosed with early distal type intestinal gastric adenocarcinoma (group one) and 58 
with advanced distal type intestinal gastric adenocarcinoma (group two). The mean ages of 
group one were 61.0 years, with 20 male cases (64.5%) and 11 female cases (35.5%). For 
group two the mean ages was 64.5 years, with 40 male cases (69.0%) and 18 female cases 
(31.0%). All the gastric tissue samples were obtained from endoscopic biopsy and had 
positive results for H. pylori by histological analysis. Samples from gastric tissues obtained 
by endoscopic biopsy of patients with chronic gastritis and peptic ulcers were used as a 
control for all the reactions performed in this study. Primer pairs were chosen in order to 
amplify final products with similar length (base pairs) and, with this aim, only for the cagA 
gene, we used the nested PCR. Finally, all the stages of this study were approved by the 
Ethics Committee of the Faculty of Medical Sciences, State University of Campinas 
(UNICAMP). 
2.2 Methods  
2.2.1 DNA extraction 
Paraffin wax-embedded tissue DNA extraction was performed by carrying out the pre-
extraction treatment of fixed tissues, using xylene and ethanol washes for paraffin removal. 
Subsequently, successive steps using proteinase K, phenol, chloroform and isoamyl alcohol 
were carried out, in order to isolate and purify the DNA (Goelz et al., 1985). Quantification 
of the extracted DNA and polymerase chain reaction (PCR) for human betaglobin gene 
(Saiki et al., 1988) were carried out in order to guarantee the quality of this research. 
2.2.2 PCR for urease C, vacA (regions s and m), cagA, cagT and dupA (regions 
jhp0917 and jhp0918) genes 
Primer pairs for all the genes are described in Table 1, as well as the length of the fragments 
amplified for each reaction: urease C (Lage et al., 1995), vacA s1/s2 (Atherton et al., 1997), 
vacA m1/m2 (Atherton et al., 1999; Thomazini et al., 2006), cagA (Faundez et al., 2002), cagT 
(Mattar et al., 2007) and dupA jhp0917 and jhp0918 (Lu et al., 2005). PCR for urease C gene 
was performed with the aim to identify the bacterium DNA in samples.  
After amplification, each PCR product was submitted to eletrophoresis on a 2% agarose gel 
stained by ethidium bromide with a 0.5 X tris-acetate-EDTA buffer. A 100-bp ladder was 
used as standard. 
Then, for each specific reaction, after being tested positive for urease C gene, products 
obtained were classified in vacA s1m1, s2m1, s1m2 or s2m2, cagA positive or negative, cagT 
positive or negative, dupA jhp0917 positive or negative and dupA jhp0918 positive or 
negative; dupA gene was considered positive when its two regions were positive 
simultaneously.  
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Gene Strand Primer sequence (5´ - 3´) Length (bp) 
Betaglobin + ACACAACTGTGTTCACTAGC 110 
 - CAACTTCATCCACGTTTCACC  
Urease C + AAGCTTTTAGGGGTGTTAGGGGTTT 294 
 - AAGCTTACTTTCTAACACTAACGC  
vacA s (s1/s2) + ATGGAAATACAACAAACACAC  S1,259; s2: 286 
 - CTGCTTGAATGCGCCAAAC  
vacA m1 + GGTCAAAATGCGGTCATGG 290 
 - CCATTGGTACCTGTAGAAAC  
vacA m2 + ATGCTTTAATATCGTTGAGA 198 
 - GAA CAT GTT TTA GTG AAA GC  
cagA (1st PCR) + GATAACAGGCAAGCTTTTGAGAGGG
A 
393 
 - CCATGAATTTTTGATCCGTTCGG  
cagA (nested) + GATAACAGGCAAGCTTTTGAGG 349 
 - CTGCAAAAGATTGTTTGGCAGA  
cagT + CCATGTTTATACGCCTGTGT 301 
 - CATCACCACACCCTTTTGAT  
dupA (jhp0917) + TGGTTTCTACTGACAGAGCGC 307 
 - AACACGCTGACAGGACAATCTCCC  
dupA (jhp0918) + CCTATATCGCTAACGCGCGCTC 276 
 - AAGCTGAAGCGTTTGTAACG  
Table 1. Sequence of synthetic oligonucleotide primers used to characterization of H. pylori 
strains  
2.2.3 Statistical analysis 
After all amplification reactions, the results were analysed by a chi-square test at the 
Statistical Service of the Faculty of Medical Sciences at UNICAMP. Results were then related 
to the diseases in study, observing possible differences among H. pylori strains encountered 
in early and in advanced distal type intestinal gastric adenocarcinoma. Values of p<0.05 
were considered to be statistically significant. The results as a whole, after comparison 
between the two groups, were depicted. Odd ratios with a confidence interval of 95% were 
also observed. Tables with absolute frequencies (n) and percentages (%) were made in order 
to determine genotypes combinations. Then, Exact Fischer´s Test was used in order to 
compare the genotypes combinations between early and advanced gastric cancer. Values of 
p<0.05 were considered to be statistically significant. 
2.3 Results 
PCR for the urease C gene of H. pylori was positive in all 89 samples, identifying the 
bacterium DNA (Table 2; Figure 5). For the vacA gene, with regard to region s, of 31 
samples from patients with early gastric cancer, 71.0% (22 cases) were s1 and 29.0% (9 cases) 
s2. Fifty eight samples from patients with advanced gastric cancer, 70.7% (41 cases) were s1 
and 29.3% (17 cases) s2 (p = 0.978) (Table 2; Figure 6). In conclusion, 63 (70.8%) samples 
were diagnosed with vacA subtype s1 and 26 (29.2%) samples were with subtype vacA s2. 
Related to the vacA gene subunit m, no positive results were observed for the vacA gene 
subunit m2. From all 89 samples, 31 patients with early gastric cancer and 58 patients with 
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advanced gastric cancer were m1 positive (Table 2; Figure 7). Following this analysis, 
samples were classified into s1m1 or s2m1. For patients with early gastric cancer, 71.0% (22 
cases) were s1m1 and 29.0% (9 cases) were s2m1. From 58 samples of patients with 
advanced gastric cancer, 70.7% (41 cases) were s1m1 and 29.3% (17 cases) s2m1 (table 3). 
Results were not statistically significant (p = 0.978). In conclusion, 63 (70.8%) samples were 
vacA s1m1 and 26 (29.2%) were vacA s2m1 (Table 2).  
Analyzing the cagA gene, from patients with early gastric cancer, 61.3% (19 cases) were 
positive and from patients with advanced gastric cancer, 82.8% (48 cases) were positive (p = 
0.025), with an odds ratio of 3.032, 95% confidence interval (1.123-8.185) (Table 2; Figure 8). 
In the group as a whole, there were 67 positive cases (75.3%) for the cagA gene. On the other 
hand, analyzing the cagT gene of H. pylori, from patients with early gastric adenocarcinoma 
54.8% (17 cases) were positive and in patients with advanced gastric adenocarcinoma, 65.5% 
(38 cases) were positive (p = 0.323) (Table 2; Figure 9). In the group there were 55 positive 
cases (61.8%) for the cagT gene. 
Results of dupA jhp0917 in patients with early gastric cancer, 35.5% (11 cases) presented 
positive results and in patients with advanced gastric cancer, 39.7% (23 cases) presented 
positive (p = 0.700) (Table 2; Figure 10). In the group as a whole, there were 34 positive 
cases (38.2%) and 55 negative cases (61.8%) for jhp0917.  Tests of dupA jhp0918 in patients 
with early gastric cancer, 51.6% (16 cases) had positive results and In patients with advanced 
gastric cancer, 55.2% (32 cases) were positive (p = 0.748) (Table 2; Figure 11). The p  
value obtained was 0.748, which was not statistically significant. In the group there were 48 
cases (53.9%) that were positive for dupA jhp0918 gene and 41 cases (46.1%) that were 
negative. 
 
Classification Early gastric 
cancer 
Advanced gastric 
cancer 
Total p value 
urease C 31 (100.0%) 58 (100.0%) 89 (100.0%)  
s1 22 (71.0%) 41 (70.7%) 63 (70.8%)  
s2 9 (29.0%) 17 (29.3%) 26 (29.2%) p = 0.978 
m1 31 (100.0%) 58 (100.0%) 89 (100.0%)  
m2 0 (0.0%) 0 (0.0%) 0 (0.0%)  
s1m1 22 (71.0%) 41 (70.7%) 63 (70.8%)  
s2m1 9 (29.0%) 17 (29.3%) 26 (29.2%) p = 0.978 
cagA positive 19 (61.3%) 48 (82.8%) 67 (75.3%)  
cagA negative 12 (38.7%) 10 (17.2%) 22 (24.7%) p = 0.025* 
cagT positive 17 (54.8%) 38 (65.5%) 55 (61.8%)  
cagT negative 14 (45.2%) 20 (34.5%) 34 (38.2%) p = 0.323 
dupA jhp0917 positive 11 (35.5%) 23 (39.7%) 34 (38.2%)  
dupA jhp0917 negative  20 (64.5%) 35 (60.3%) 55 (61.8%) P = 0.700 
dupA jhp0918 positive 16 (51.6%) 32 (55.2%) 48 (53.9%)  
dupA jhp0918 negative 15 (48.4%) 26 (44.8%) 41 (46.1%) P = 0.748 
Total 31 (100.0%) 58 (100.0%) 89 (100.0%)  
* cagA gene (p = 0.025), OR = 3.032 (95% CI, 1.123-8.185) 
Table 2. General results obtained after reactions for urease C, vacA (s/m), cagA, cagT and 
dupA jhp0917 and jhp0918 genes of Helicobacter pylori 
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     L    C+  01   02   03   C- 
 
Fig. 5. Amplification of the urease C gene of H. pylori (294 bp); L, ladder 100 bp; C+, positive 
control; 01 to 03, positive samples; C-, negative control. 
 
 
                 C+  C+ 
           L    s1    s2   01    02    03     04    C- 
 
Fig. 6. Amplification of the vacA region s gene of H. pylori (s1, 259 bp; s2, 286 bp); L, ladder 
100 bp; C+s1, positive control for vacA s1; C+s2, positive control for vacA s2; 01 and 03, 
positive samples for s1; 02 and 04, positive samples for s2; C-, negative control. 
 
 
                               C+ 
            L  m1  01  02  03   04   C- 
                                 
Fig. 7. Amplification of the vacA m1 region of H. pylori (290 bp). L, ladder 100 bp; C+ m1, 
positive control for vacA m1; 01 to 04, positive samples; C-, negative control.  
294 bp 
s1 = 259 bp 
s2 = 286 bp 
290 bp 
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    L    C+ 01  02   03   04  05   C- 
          
Fig. 8. Amplification of cagA gene of H. pylori (349 bp). L, ladder 100 bp; C+, positive 
control; 01 to 05, positive samples; C-, negative control.  
 
 
 
 
                     L    C+ 01  02   03   04  05   C- 
                            
Fig. 9. Amplification of cagT gene of H. pylori (301 bp). L, ladder 100 bp; C+, positive control; 
01 to 05, positive samples; C-, negative control. 
 
 
 
 
                       L   C+ 01  02  03 04  C- 
 
Fig. 10. Amplification of dupA jhp0917 gene of H. pylori (307 bp). L, ladder 100 bp; C+, 
positive control; 01 to 04, positive samples; C-, negative control. 
349 bp 
301 bp 
307 bp 
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L   C+ 01  02  03  C- 
                         
Fig. 11. Amplification of dupA jhp0918 gene of H. pylori (276 bp). L, ladder 100 bp; C+, 
positive control; 01 to 03, positive samples; C-, negative control. 
After this analysis, tables with absolute frequencies (n) and percentages (%) were made in 
order to compare the genotypes combinations. vacA s1m1, cagA positive, cagT positive and 
dupA negative were, individually, the most frequent genotypes (Table 3). In order to 
specify better the results obtained, the dupA gene was considered positive when its two 
continuous regions (jhp0917 and jhp0918) were positive simultaneously. So, the 
combinations of genotypes were made and then compared between the two groups of 
patients, with early and advanced gastric cancer (Tables 4 and 5, respectively). The most 
prevalent genotype for all the samples, in both groups of patients, was vacA s1m1, cagA 
positive, cagT positive and dupA negative. The percentage was 29.21%. About the 
comparison of genotypes combinations between the two groups of samples, there was not a 
significant difference (p = 0.116).  
 
 
Genomic region Frequence 
(n) 
Percentage 
(%) 
vacA s/m gene s1m1 63 70.79 
s2m1 26 29.21 
cagA gene positive 67 75.28 
negative 22 24.72 
cagT gene positive 55 61.80 
negative 34 38.20 
dupA jhp0917 gene positive 34 38.20 
negative 55 61.80 
dupA jhp0918 gene positive 48 53.93 
negative 41 46.07 
dupA jhp0917/0918 gene 
  
positive 28 31.46 
negative 61 68.54 
Table 3. Descriptive analysis of genomic regions of H. pylori 
276 bp 
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Genotypes combinations: 
vacA s/m, cagA, cagT, dupA (jhp0917/0918) 
Frequency 
(n) 
Percentage 
(%) 
s1m1   neg   neg   neg 8 8.99 
s1m1   neg   neg   pos 1 1.12 
s2m1   neg   neg   neg 3 3.37 
s2m1   neg   neg   pos 2 2.25 
s1m1   neg   pos   neg  3 3.37 
s1m1   neg   pos   pos 1 1.12 
s2m1   neg   pos   neg 2 2.25 
s2m1   neg   pos   pos 2 2.25 
s1m1   pos   neg   neg 9 10.11 
s1m1   pos   neg   pos 6 6.74 
s2m1   pos   neg   neg 4 4.49 
s2m1   pos   neg   pos 1 1.12 
s1m1   pos   pos   neg 26 29.21 
s1m1   pos   pos   pos 9 10.11 
s2m1   pos   pos   neg 6 6.74 
s2m1   pos   pos   pos 6 6.74 
Table 4. Genotype combinations, according to the results obtained for vacA s/m, cagA, cagT 
and dupA (jhp0917/0918) genes of H. pylori 
 
Genotype combinations: 
vacA s/m, cagA, cagT, dupA (jhp0917/0918) 
Early gastric 
câncer 
Advanced 
gastric cancer 
Total 
s1m1   neg   neg   neg 4
12.90
4
6.90
8 
s1m1   neg   neg   pos 1
3.23
0
0.00
1 
s2m1   neg   neg   neg 1
3.23
2
3.45
3 
s2m1   neg   neg   pos 0
0.00
2
3.45
2 
s1m1   neg   pos   neg 2
6.45
1
1.72
3 
s1m1   neg   pos   pos 1
3.23
0
0.00
1 
s2m1   neg   pos   neg 2
6.45
0
0.00
2 
s2m1   neg   pos   pos 1
3.23
1
1.72
2 
s1m1   pos   neg   neg 3
9.68
6
10.34
9 
s1m1   pos   neg   pos 2
6.45
4
6.90
6 
s2m1   pos   neg   neg 2
6.45
2
3.45
4 
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Genotype combinations: 
vacA s/m, cagA, cagT, dupA (jhp0917/0918) 
Early gastric 
câncer 
Advanced 
gastric cancer 
Total 
s2m1   pos   neg   pos 1 
3.23 
0 
0.00 
1 
s1m1   pos   pos   neg 5 
16.13 
21 
36.21 
26 
s1m1   pos   pos   pos 4 
12.90 
5 
8.62 
9 
s2m1   pos   pos   neg 2 
6.45 
4 
6.90 
6 
s2m1   pos   pos   pos 0 
0.00 
6 
10.34 
6 
Total 31 58 89 
p = 0.116 
Table 5. Comparison of genotypes combinations between early and advanced gastric cancer. 
3. Conclusions 
The understanding of gastric carcinogenesis has advanced considerably in recent decades, 
especially as regards to the role of Helicobacter pylori in the progression of chronic gastritis in 
precancerous lesions and cancer (de Vries et al., 2007). The risk of development of gastric 
cancer is also related to genetic characteristics of the host and environmental factors, which, 
associated with specific bacterial strain characteristics, influence the severity of the chronic 
inflammatory response (Peek et al., 1999). Thus, although infection with H. pylori almost 
always results in chronic active gastritis, many infected patients do not develop any 
complication, even those not showing clinical symptoms of infection (Blaser & Atherton, 
2004). This leads to the conclusion that some strains are more virulent than others (Kusters 
et al., 2006), expressing, in different manners, specific bacterial products. 
In the present study, we compared the H. pylori strains obtained from patients with early 
and advanced distal type intestinal gastric adenocarcinoma with the aim to identify possible 
differences among strains present in one or other case, using the polymerase chain reaction 
(PCR) for several bacterial genome regions. The primary detection of H. pylori in the samples 
was performed using the urease C region, present in all strains. After this, PCR was used for 
amplifying two genes from the cagPAI (cagA and cagT), the vacA gene (regions s and m) 
and the dupA gene (jhp0917/0918). 
Strains with an s1-type signalling-sequence allele produce functional VacA toxin, whereas 
those with an s2-type signalling sequence have little cytotoxic activity (Peek & Blaser, 2002). 
Moreover, mosaic s1m1 strains are more toxic than s1m2 strains and are associated with 
more severe forms of gastritis, atrophy and intestinal metaplasia (Björkholm et al., 2003). 
The presence of s1 m1 vacA alleles is also strongly correlated with the expression of the cag-
PAI (Covacci et al., 1993; Tummuru et al., 1993). Although located on a different loci of the 
H. pylori chromosome, cagA is strongly linked with VacA cytotoxic activity (Hocker & 
Hohenberger, 2003) and strains expressing the combination of these alleles and cag-PAI 
show enhanced epithelial cell injury (Ghiara et al., 1995). In our study, for patients with 
advanced gastric cancer, we found prevalent cagA positive (82.8%) and vacA s1m1 (70.7%) 
strains, corroborating the results of other studies (Miehlke et al., 2000; Leanza et al., 2004), 
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and demonstrating that this combination can result in more virulent strains. These results 
are also similar to those obtained in China (Qiao et al., 2003), where H. pylori strains were 
cagA positive in 95% of samples in the gastric cancer group and the expression of type s1 
vacA was more than type s2. Nevertheless, with respect to type m, the expression of type 
m1 was equal to type m2, even in the gastric cancer group. In our study we did not find a 
positive result for m2.      
With regards to early gastric cancer patients, unless we found strains with the same 
characteristics to those of advanced gastric cancer, some samples (cagA positive for 61.3% of 
samples and vacA s1m1 for 71.0% of samples), were positive for cagA and vacA s2m1 
(29.0%), which may contribute for the maintenance of the early stage of disease. In addition, 
one possible explanation would be that the strains found in early lesions, in relation to the 
cagA gene, could be different which respects to their EPYIA motifs (polymorfisms of the 
cagA gene) (Nguyen et al., 2009; Truong et al., 2009), leading to the maintenance of early 
stage disease, without its progression to advanced lesions.  
As regards to the cagA gene, in an isolate analysis, our results were similar to those of in 
which strains cagA positive were related to the development of gastric cancer. cagA positive 
strains tend to be more virulent and induce higher levels of expression of cytokines such as 
interleukin 1b and 8 (El-Omar et al., 2000). Some studies have shown that patients with 
strains that express CagA are three times more likely to develop gastric cancer [Parsonnet et 
al., 1997; Huang et al., 2003) than those infected with cagA negative strains (Husson et al., 
1995; Yamaoka et al., 1999). In the present study the same characteristics were observed and 
patients infected with cagA positive strains demonstrated a high risk of advanced gastric 
cancer development (OR = 3.032, 95%CI). Besides, studies conducted in Western countries 
(Crabtree et al., 1994; Blaser et al., 1995) and in Asian countries (Mizushima et al., 2001) 
reported that most patients with gastric cancer are infected with H. pylori cagA positive 
strains.   
Like the cagA gene, the cagT also belongs to the cag pathogenicity island and it is assumed 
that it is related to the type IV secretion system, responsible for binding to cell receptors and 
inducing the release of interleukin-8 and also by ejecting the CagA protein (Rohde et al., 
2003). The cagT gene has been linked to the development of peptic ulcer, and strains with 
the absence of this gene were generally related to chronic gastritis (Mattar et al., 2007). In 
this study, values were not found to be statistically significant between the two studied 
groups (p = 0.323). However, the cagT gene was found, in the group as a whole, in 61.8% of 
the samples, which reflects a significant result, showing that this gene, like cagA, or acting 
together with cagA, may be related to gastric cancer development.  
Finally, for the dupA gene, which was originally considered a marker for duodenal ulcer 
disease and a protective factor against gastric cancer in strains isolated from Japan, Korea 
and Colombia (Lu et al., 2005), we did not find any statistically significant difference 
between the two studied groups. Thus, although the dupA gene can not be considered as a 
marker for duodenal ulcer disease, the presence of this gene was found in few samples of 
patients with gastric cancer, suggesting that it is not an important gene for the development 
of this disease, by itself. Conversely, dupA genotyping of samples obtained from four 
populations (Argent et al., 2008), from Belgium, South Africa, China and the United States of 
America, showed no association of this gene with duodenal ulcer, but suggested an 
association with gastric cancer. Another study carried out in Brazilian patients (Gomes et al., 
2008) also did not find any association between dupA and either of the two diseases. Finally, 
in India, a study demonstrated a significant association of dupA gene with duodenal ulcer 
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disease in the population (Arachchi et al., 2007). These different results demonstrate that 
further studies are required to elucidate the roles of dupA gene in the development of 
gastric diseases.  
There are a number of studies that have investigated the virulence factors of H. pylori 
strains, but a gene marker for gastric cancer disease has not yet been found. Our study has 
demonstrated an interaction between some virulence factors found in gastric tissue samples 
obtained by early and advanced distal type intestinal gastric adenocarcinoma and a 
significant statistically value for cagA gene, which is more present in patients with 
advanced cancer. In the group gastric cancer as a whole, we found a prevalence of cagA 
positive, cagT positive, vacA s1m1 strains genotypes and a low number of dupA positive 
samples. Between the two groups, there were no statistically differences about the most 
prevalent combination of genotypes. In conclusion, the identification of a disease specific H. 
pylori virulence factor could be useful in clinical practice, helping to identify patients 
infected with strains that are able to develop a serious disease, such as gastric cancer.      
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